Secondary hyperparathyroidism in advanced prostate cancer;Hiperparatiroidismo secundario en el cáncer de próstata avanzado

Endocrinologia y Nutricion

Volumn 57, Issue 3, 2010, Pages 100-104

  Quirosa Flores, Susana ^a   Varsavsky, Mariela ^a   Valle Díaz De La Guardia, Francisco ^a   Miján Ortiz, Jose Luis ^a   Muñoz Torres, Manuel ^a   Raya Álvarez, Enrique ^a   Zuluaga Gómez, Armando ^a  

^a HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

Author keywords

Bone metabolism; Hyperparathyroidism; Prostate cancer

Indexed keywords

CALCIUM; PARATHYROID HORMONE; PHOSPHORUS; PROSTATE SPECIFIC ANTIGEN; VITAMIN D;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CONTROLLED STUDY; DISEASE COURSE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RETROSPECTIVE STUDY; SECONDARY HYPERPARATHYROIDISM;

AGED; DISEASE PROGRESSION; HUMANS; HYPERPARATHYROIDISM, SECONDARY; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77950826114     PISSN: 15750922     EISSN: 15792021     Source Type: Journal    
DOI: 10.1016/j.endonu.2010.01.013     Document Type: Article

References (24)

1. Caballero J., Marchal C., Padilla M., and Rodrigo I. Aumento de la tasa cruda de la incidencia del cáncer de próstata en nuestro medio. Actas Urol Esp 25 (2001) 624-627
2. Guise T.A. Parathyroid hormone-related protein and bone metastases. Cancer 80 (1997) 1572-1580
3. Roodman D. Mechanisms of bone metastasis. N Engl J Med 350 (2004) 16-20
4. Guise T.A. The vicious cycle of bone metastases. J Musculoskelet Neuronal Interact 2 (2002) 570-572
5. Garnero P. Markers of bone turnover in prostate cancer. Cancer Treat Rev 27 (2001) 187-192
6. Gennari L., and Bilezikian J.P. Osteoporosis in men. Endocrinol Metab Clin North Am 36 (2007) 399-419
7. Gary G. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers 17 (2008) 478-483
8. Carvallido J.A. Cáncer de próstata avanzado. Inf Ter Sist Nac Salud 22 (1998) 33-43
9. Rodríguez M., Ferrer E., and Ferrer C. Tratamiento multidisciplinario actual del cáncer de próstata metastásico. Actas Urol Esp 27 (2003) 767-782
10. Platz E.A., Leitzmann M.F., Hollis B.W., Willet W.C., and Giovannucci E. Plasma 1,25-dihydroxy-and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control 15 (2004) 255-265
11. Deeb K.K., Trump D.L., and Johnson C.S. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 7 (2007) 684-700
12. Peehl D.M., and Feldman D. The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 10 (2003) 131-140
13. Tandon P.K., and Rizvi A.A. Hypocalcemia and parathyroid function in metastatic prostate cancer. Endocr Pract 11 (2005) 254-258
14. Giovannucci E., Liu Y., Stampfer M., and Willett W. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomarkers Prev 15 (2006) 203-210
15. Baron J.A., Beach M., Wallace K., Grau M.V., Sandler R.S., Mandel J.S., et al. Risk of prostate cancer in a randomized clinical trial of calcium supplementation. Cancer Epidemiol Biomarkers Prev 14 (2005) 586-589
16. Bonjour J.P., Chevalley T., and Fardellone P. Calcium intake and vitamin D metabolism and action, in healthy conditions and in prostate cancer. Br J Nutr 97 (2007) 611-616
17. McCarty M.F. Parathyroid hormone may be a cancer promoter- an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and vitamin D. Med Hypotheses 54 (2000) 475-482
18. Bilezikian J.P. Osteoporosis in men. J Clin Endocrinol Metab 84 (1999) 3431-3434
19. Orwoll E.S., Ettinger M., Weiss S., Miller P., Kendler D., Graham J., et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 9 (2000) 604-610
20. Gary G., and Schwartz. Prostate cancer, serum parathyroid hormone, and the progression of skeletal metastases. Cancer Epidemiol Biomarkers Prev 17 (2008) 478-483
21. Cosman F., and Lindsay R. Therapeutic potential of parathyroid hormone. Curr Osteoporos Rep 2 (2004) 5-11
22. Murray R.M., Grill V., Crinis N., Ho P.W., Davison J., and Pitt P. Hypocalcemic and normocalcemic hyperparathyroidism in patients with advanced prostatic cancer. J Clin Endocrinol Metab 86 (2001) 4133-4138
23. Schwartz G.G., Hall M.C., Stindt D., Patton S., Lovato J., and Torti F.M. Phase I/II study of 19-nor-1A-25-dihydroxyvitamin D2 (paricalcitol) in advanced, androgen-insensitive prostate cancer. Clin Cancer Res 11 (2005) 8680-8685
24. Tamada T., Sone T., Tomomitsu T., Jo Y., Tanaka H., and Fukunaga M. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy. J Bone Miner Metab 19 (2001) 45-51